Skip to main content

Pacira BioSciences Inc

For the period ended Mar 31, 2024. Filed May 7, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 7, 2024

PCRX$36.46+0.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 5. Other Information

Rule 10b5-1 Trading Plans

The following table shows the “Rule 10b5-1 trading arrangements” and “non-Rule 10b5-1 trading arrangements” (as each term is defined in Item 408(a) of Regulation S-K)adopted by our directors and executive officers during the quarter ended March 31, 2024. No trading arrangements were terminated by our directors and executive officers during the quarter ended March 31, 2024.

Trading Arrangement
Name and Position · Action · Date · Rule 10b5-1* · Non-Rule10b5-1** · Total Number ofShares to be Sold · ExpirationDate
Lauren RikerPrincipal Accounting OfficerAdopt3/5/2024xTo Be Determined (1)12/31/2024
Kristen WilliamsChief Administrative Officer and SecretaryAdopt3/8/2024xTo Be Determined (1)6/28/2024
Jonathan SloninChief Medical OfficerAdopt3/8/2024xTo Be Determined (1)1/31/2025
Paul HastingsDirectorAdopt3/12/2024x1,77512/31/2024
Daryl GauglerChief Operating OfficerAdopt3/12/2024x2,5003/7/2025
  • Intended to satisfy the affirmative defense of Rule 10b5-1(c).

** Not intended to satisfy the affirmative defense of Rule 10b5-1(c).

(1) The aggregate number of shares to be sold pursuant to each trading arrangement listed above is dependent on the amount of tax withholding required upon the vesting of restricted stock units, and, therefore, is indeterminable at this time.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.